1092 Results
Sort By:
Published on November 6, 2017
Researchers at the Broad Institute of MIT and Harvard, Koch Institute at MIT, Dana-Farber Cancer Institute (DFCI), and Massachusetts General Hospital have just released data demonstrating that nearly 90% of a tumor's genetic features can be detected in blood samples using whole-exome sequencing, and that the method can be effectively…
Published on November 6, 2017
Seven Bridges said today it has been selected by the NIH to lead a public-private consortium that will develop the pilot phase of a new data ecosystem for the agency. The Data Commons Pilot Phase is NIH’s latest effort to accelerate biomedical research through informatics, with the goal of advancing…
Published on October 30, 2017
For the first time, say researchers, comprehensive DNA and RNA sequencing of a patient's tumor have been used in a clinical trial to inform real-time treatment for patients with recurring glioblastoma. The Translational Genomics Research Institute (TGen), University of California, San Francisco (UCSF), and the Ivy Foundation Early Phase Clinical…
Published on October 25, 2017
Vantari Genetics and Translational Software® (TSI) said they will support the Banner Alzheimer’s Institute’s (BAI) GeneMatch registry by providing genotype testing, actionable genomic information and custom reporting, through a collaboration whose value was not disclosed. GeneMatch is a national program led by BAI that is designed to help recruit participants for…
Published on October 10, 2017
According to Jose Castro-Perez, Ph.D., director of global markets, Health Sciences with Waters, mass spectrometry today is an underused technology in the clinical lab. But it is one that can play a significant role to help guide early treatment and preventative care, especially diseases that are significantly caused, or influenced,…
Published on October 8, 2017
For you, why is a biomarker and diagnostic strategy so important and where is the most value gained from this approach? In Alzheimer’s disease (AD) drug development, over the past 15 years everything has failed. We finally understand and are targeting amyloid oligomers – the key pathogen of Alzheimer’s. Also,…
Published on September 22, 2017
Patient-centric genomics company DxTerity announced it will collaborate with California-based City or Hope Medical Center on the clinical development of a blood test intended to predict whether patients about to undergo radiation therapy for cancer are likely to benefit from the treatment. The test will also seek to provide information…
Published on September 11, 2017
Qiagen has selected Angle’s Parsortix system as its circulating tumor cell (CTC) harvesting technology, and Parsortix will be cross-promoted with Qiagen’s liquid biopsy solution portfolio, the companies said today, through a co-marketing agreement whose value was not disclosed. Angle and Qiagen have agreed to market to their customers the offerings…
Published on September 6, 2017
Epic Sciences said today its researchers have partnered with investigators at Memorial Sloan Kettering Cancer Center (MSK) to develop and apply a new liquid biopsy blood test shown to measure resistance to targeted therapies in metastatic castration-resistant prostate cancer (mCRPC) patients. The test—which measures tumor heterogeneity through analysis of single…
Published on August 28, 2017
MedGenome said today it has completed a $30 million Series C financing, with the genomics research and diagnostics company directing proceeds toward its biomarker discovery programs and further development of its OncoPept™ suite of cancer immunotherapy biomarker solutions. The financing will allow genomic and biopharma researchers in the U.S. and…
Published on August 22, 2017
Aiming to improve upon current T cell treatments, CRISPR Therapeutics and Massachusetts General Hospital Cancer Center (MGHCC) and said today they will use CRISPR/Cas9 gene editing to develop novel T cell therapies for blood and solid tumors. The value of the collaboration was not disclosed. CRISPR Therapeutics said the collaboration…
Published on August 11, 2017
Four-year-old genetic testing company Color Genomics has announced its first foray outside the hereditary cancer screening area with the launch of a familial hypercholesterolemia (FH) screening test. FH is an hereditary genetic disorder that manifests in very high levels of cholesterol and elevated levels of LDL—or “bad” cholesterol—in the blood.…
Published on August 3, 2017
With it’s 150,000th patient recently enrolled, Geisinger Health System’s MyCode project is helping set the standard for big health data projects around the world. The program has a system to easily enroll patients, process both their genomic and clinical data, return relevant results to them, and spur research. It’s what…
Published on July 12, 2017
Researchers at the New York Genome Center (NYGC), The Rockefeller University, and other NYGC member institutions recently demonstrated the potential of IBM Watson for Genomics to analyze complex genomic data from state-of-the-art DNA sequencing of whole genomes and provide a report of potential clinically actionable insights within 10 minutes. The proof-of-concept…
Published on June 20, 2017
Agena Bioscience said today that its MassARRAY® System has been chosen by Assurex Health for laboratory setup and sample processing of its GeneSight Psychotropic test, under an expanded partnership whose value was not disclosed. GeneSight Psychotropic is a laboratory-developed test designed to help clinicians analyze how a patient's genetic make-up…